Xu Jianguo, Gui Ge Sang Wang, Yang Chao, Zhu Shuchen, Chen Zemin, Ma Suo Lang Bai, Yang Ci, Bu Ci Ren Luo, Zhu Ying, Xu Wen
Department of Liver Disease Center, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China.
Medical Department, Chayu County People's Hospital, Chayu, Xizang, China.
Curr Mol Med. 2024;24(5):667-675. doi: 10.2174/0115665240258296231024112309.
USPs are a family of enzymes that regulate protein degradation, and their dysregulation has been implicated in the development and progression of cancer.
This study aimed to determine whether ubiquitin-specific proteases 3 (USP3) could be a potential target for therapy in hepatocellular carcinoma (HCC), particularly in resistant HCC. This study systematically investigated the role of USP3 in HCC, with a focus on chemo-resistant HCC cells.
The level of USP3 from clinical samples was measured using an ELISA assay. Cell proliferation, apoptosis, migration, and anchorage-independent colony formation assays were performed. Transfection was performed to knock down USP3 expression and measure β-catenin activity, and real-time PCR was used to measure levels of MYC and CYCLIN D1 genes.
USP3 protein was upregulated in HCC tissues, but its upregulation was not associated with clinicopathology. USP3 knockdown had a similar inhibitory effect on growth in both sensitive and resistant HCC cells, did not affect migration, and induced apoptosis in sensitive but not resistant HCC cells. Furthermore, USP3 knockdown was more effective in suppressing anchorage-independent colony formation in chemoresistant HCC cells compared to their chemo-sensitive counterparts. Pearson correlation coefficient analysis revealed a strong positive correlation between USP3 and CTNNB1, and consistently, USP3 knockdown reduced the levels and activities of β-catenin in HCC cells. Using a Wnt activator (lithium) in rescue studies significantly reversed the inhibitory effects of USP3 knockdown.
The findings suggest that inhibiting USP3 is an effective strategy against cancer stem cells and chemo-resistant HCC cells.
泛素特异性蛋白酶(USP)是一类调节蛋白质降解的酶,其失调与癌症的发生和发展有关。
本研究旨在确定泛素特异性蛋白酶3(USP3)是否可能成为肝细胞癌(HCC)治疗的潜在靶点,特别是在耐药性HCC中。本研究系统地研究了USP3在HCC中的作用,重点是化疗耐药的HCC细胞。
采用酶联免疫吸附测定(ELISA)法检测临床样本中USP3的水平。进行细胞增殖、凋亡、迁移和非锚定依赖性集落形成试验。进行转染以敲低USP3表达并测量β-连环蛋白活性,使用实时聚合酶链反应(PCR)测量MYC和细胞周期蛋白D1基因的水平。
USP3蛋白在HCC组织中上调,但其上调与临床病理无关。USP3敲低对敏感和耐药HCC细胞的生长均有类似的抑制作用,不影响迁移,并诱导敏感而非耐药HCC细胞凋亡。此外,与化疗敏感的HCC细胞相比,USP敲低在抑制化疗耐药的HCC细胞非锚定依赖性集落形成方面更有效。Pearson相关系数分析显示USP3与CTNNB1之间存在强正相关,并且一致地,USP3敲低降低了HCC细胞中β-连环蛋白的水平和活性。在挽救研究中使用Wnt激活剂(锂)可显著逆转USP3敲低的抑制作用。
研究结果表明,抑制USP3是对抗癌症干细胞和化疗耐药HCC细胞的有效策略。